Aims Worldwide observational studies are evidencing discordance between guidelines and
real‐world practice regarding direct oral anticoagulant drug (DOAC) doses. This systematic …

Background & Aims There is controversy over whether use of non-vitamin K antagonist oral
anticoagulants (NOACs) associates with increased risk of major gastrointestinal bleeding …

Background: Advanced liver disease is known to increase the risk for bleeding and affects
the hepatic clearance and metabolism of drugs. Subjects with active liver disease were …

Background: Prescriptions of off-label under-and overdosing of direct oral anticoagulants
(DOACs) are common for patients with atrial fibrillation, but their efficacy and safety remain …

Background Whether four direct oral anticoagulants (DOACs) are superior to warfarin in
Asian patients with nonvalvular atrial fibrillation (NVAF) remains unclear. Methods This …

Background Off-label dosing non–vitamin K antagonist oral anticoagulants (NOACs) are
commonly prescribed for Asian patients with atrial fibrillation (AF). Objective The purpose of …

Background and Purpose—Limited evidence exists on the effectiveness and safety of
warfarin and all 4 available non-vitamin K antagonist oral anticoagulants (NOACs) from …

Background and Purpose—Limited data are available describing the relative effectiveness,
safety, and optimal dosing of non–vitamin K antagonist oral anticoagulants (NOACs) for …

Importance Current guidelines recommend the use of non–vitamin K antagonist oral
anticoagulants (NOACs) for stroke prevention in patients with atrial fibrillation (AF). Data …

Background Liver cirrhotic patients with nonvalvular atrial fibrillation have been excluded
from randomized clinical studies regarding oral anticoagulants for stroke prevention …